Meridian Bioscience, Inc. (VIVO) Misses Q2 EPS by 4c; Cuts FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.17, $0.04 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $40.05 million versus the consensus estimate of $43.13 million.
Meridian Bioscience, Inc. sees FY2011 EPS of $0.68-$0.71, versus prior guidance of $0.77-$0.82 and the consensus of $0.79.
Meridian Bioscience, Inc. sees FY2011 EPS of $0.68-$0.71, versus prior guidance of $0.77-$0.82 and the consensus of $0.79.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VivoPower shifts focus to AI data centers, revises unit spinoff plans
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Rivian raises 2026 delivery outlook after Q2 results top guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
